Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches.

Inhibition of farnesyltransferase (FT) enzyme by a set of 78 thiol and non-thiol peptidomimetic inhibitors was successfully modeled by a genetic neural network (GNN) approach, using radial distribution function descriptors. A linear model was unable to successfully fit the whole data set; however, the optimum Bayesian regularized neural network model described about 87% inhibitory activity variance with a relevant predictive power measured by q2 values of leave-one-out and leave-group-out cross-validations of about 0.7. According to their activity levels, thiol and non-thiol inhibitors were well-distributed in a topological map, built with the inputs of the optimum non-linear predictor. Furthermore, descriptors in the GNN model suggested the occurrence of a strong dependence of FT inhibition on the molecular shape and size rather than on electronegativity or polarizability characteristics of the studied compounds.

[1]  Bahram Hemmateenejad,et al.  Genetic Algorithm Applied to the Selection of Factors in Principal Component-Artificial Neural Networks: Application to QSAR Study of Calcium Channel Antagonist Activity of 1, 4-Dihydropyridines (Nifedipine Analogous) , 2003, J. Chem. Inf. Comput. Sci..

[2]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. , 2000, Current opinion in cell biology.

[3]  J. Gasteiger,et al.  Finding the 3D structure of a molecule in its IR spectrum , 1997 .

[4]  Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase. , 1999, Bioorganic & medicinal chemistry letters.

[5]  Douglas M. Hawkins,et al.  The Problem of Overfitting , 2004, J. Chem. Inf. Model..

[6]  Bahram Hemmateenejad,et al.  Toward an Optimal Procedure for PC-ANN Model Building: Prediction of the Carcinogenic Activity of a Large Set of Drugs , 2005, J. Chem. Inf. Model..

[7]  David A Winkler,et al.  Neural networks as robust tools in drug lead discovery and development , 2004, Molecular biotechnology.

[8]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[9]  M. Schlitzer,et al.  Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. , 2002, Bioorganic & medicinal chemistry.

[10]  Frank R Burden,et al.  Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. , 2004, Journal of medicinal chemistry.

[11]  M Karplus,et al.  Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. , 1996, Journal of medicinal chemistry.

[12]  M. Karplus,et al.  Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors. , 1996, Journal of medicinal chemistry.

[13]  T. Kohonen.  Self-organized formation of topographically correct feature maps , 1982 .

[14]  F. Burden,et al.  A quantitative structure--activity relationships model for the acute toxicity of substituted benzenes to Tetrahymena pyriformis using Bayesian-regularized neural networks. , 2000, Chemical research in toxicology.

[15]  Johann Gasteiger,et al.  Deriving the 3D structure of organic molecules from their infrared spectra , 1999 .

[16]  S. Ng,et al.  Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase. , 1999, Bioorganic & medicinal chemistry letters.

[17]  Maykel Pérez González,et al.  TOPS-MODE versus DRAGON descriptors to predict permeability coefficients through low-density polyethylene , 2003, J. Comput. Aided Mol. Des..

[18]  M. Schlitzer,et al.  Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides. , 2002, Bioorganic & medicinal chemistry.

[19]  Bobby G. Sumpter,et al.  Theory and Applications of Neural Computing in Chemical Science , 1994 .

[20]  R. Lipnick.  Outliers: their origin and use in the classification of molecular mechanisms of toxicity. , 1991, The Science of the total environment.

[21]  D. Pompliano,et al.  Potent, non-thiol inhibitors of farnesyltransferase. , 1998, Bioorganic & medicinal chemistry letters.

[22]  D. Pompliano,et al.  Intramolecular fluorescence enhancement: a continuous assay of Ras farnesyl:protein transferase , 1992 .

[23]  Zhanghua Wu,et al.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. , 1998, Biochemistry.

[24]  Johann Gasteiger,et al.  Chemical Information in 3D Space , 1996, J. Chem. Inf. Comput. Sci..

[25]  Teuvo Kohonen,et al.  Self-organized formation of topologically correct feature maps , 2004, Biological Cybernetics.

[26]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[27]  C. Luttmann,et al.  Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors. , 2000, Journal of medicinal chemistry.

[28]  Maykel Pérez González,et al.  A TOPS-MODE approach to predict adenosine kinase inhibition. , 2004, Bioorganic & medicinal chemistry letters.

[29]  Yuji Takahata,et al.  Comparison between Neural Networks (NN) and Principal Component Analysis (PCA): Structure Activity Relationships of 1, 4-Dihydropyridine Calcium Channel Antagonists (Nifedipine Analogues) , 2003, J. Chem. Inf. Comput. Sci..

[30]  J. Zupan,et al.  Neural Networks in Chemistry , 1993 .

[31]  H. Díaz,et al.  A TOPS-MODE approach to predict permeability coefficients , 2004 .

[32]  M. Schlitzer,et al.  Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. , 2001, Journal of medicinal chemistry.

[33]  J. Devillers,et al.  Practical applications of quantitative structure-activity relationships (QSAR) in environmental chemistry and toxicology , 1990 .

[34]  Julio Caballero,et al.  Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks , 2006, Journal of molecular modeling.

[35]  B. Seizinger,et al.  Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. , 1996, Journal of medicinal chemistry.

[36]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[37]  S. Sebti,et al.  New approaches to anticancer drug design based on the inhibition of farnesyltransferase , 1998 .

[38]  G. Klebe,et al.  Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. , 2003, Bioorganic & medicinal chemistry.

[39]  Ernesto Estrada,et al.  A novel approach for the virtual screening and rational design of anticancer compounds. , 2000, Journal of medicinal chemistry.

[40]  Maykel Pérez González,et al.  Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. , 2005, Bioorganic & medicinal chemistry.

[41]  Johann Gasteiger,et al.  Neural networks in chemistry and drug design , 1999 .

[42]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[43]  S. Ng,et al.  Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. , 1999, Journal of medicinal chemistry.